KURE. AI, INC.

Biotech · Private

Ultra-fast CAR-T cell manufacturing process and CAR-T therapeutic product (UF-Kure19) for relapsed/refractory lymphomas

Grants
$1.5M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a novel pan-cancer CAR-T product against AML and Glioblastoma$400,000
Federal grantDepartment of Health and Human Services · Phase II · Ultra-fast manufactured CAR-T therapy$1,125,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1589REGENTIS BIOMATERIALS LTD.—$6.5M
1590LEXEO Therapeutics LLC——
1591THERANOSTEC INC——
1592KURE. AI, INC.——
1593INSILICOS——
1594FAIRBANKS PHARMACEUTICALS——
1595Resonate Industries Inc—$555K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.